Michela Adamo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michela Adamo has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Anna Ferrulli
Department of Biomedical Sciences for Health, University of Milan, Milan, Italy
5 shared publications - Livio Luzi
Department of Biomedical Sciences for Health, University of Milan, Milan, Italy
5 shared publications Concetta Macrì
Endocrinology and Metabolism Department, IRCCS Policlinico San Donato, San Donato Milanese, Italy
4 shared publicationsIleana Terruzzi
Department of Biomedical Sciences for Health, University of Milan, Milan, Italy
3 shared publications- Nelly Pitteloud
Service of Endocrinology, Diabetology, and Metabolism, Lausanne University Hospital, Lausanne, Switzerland
3 shared publications - Roberto Codella
Department of Biomedical Sciences for Health, Università degli Studi di Milano, 20133 Milan, Italy
3 shared publications
Latest Publications
- Open Access
- 14 January 2026
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (3) , 340-347
Pleiotropic genes linking congenital hypogonadotropic hypogonadism and cleft lip/palate: evidence from a genomic CHH cohort study
Congenital hypogonadotropic hypogonadism (CHH) is a rare and genetically heterogeneous disorder characterized by absent or incomplete puberty due to impaired gonadotropin-releasing hormone (GnRH) function. A subset of individuals with CHH also present with developmental anomalies, including midline defects such as cleft lip and/or palate (CLP). This study investigates the genetic overlap between CHH and CLP. A total of 336 individuals diagnosed with CHH were clinically assessed for associated phenotypes, including CLP. High-throughput sequencing was performed using a targeted gene panel encompassing known CHH- and CLP-related genes. Variants were analyzed and classified according to the American College of Medical Genetics and Genomics (ACMG) criteria for pathogenicity. CLP was present in 21 patients with CHH (6%). Pathogenic or likely pathogenic variants in genes associated with both CHH and CLP—such as FGFR1 and CHD7 —were identified in eight individuals. Furthermore, 17% of the patients with CHH without CLP harbored deleterious variants in genes implicated in clefting, including DVL3 , PLCB4 , NIPBL , and EDNRA . Evidence of digenic inheritance involving both CHH- and CLP-related genes was observed in multiple cases. FGFR1 variants were the most frequently detected and were commonly associated with anosmia and additional developmental anomalies. These findings highlight a genetic and phenotypic continuum between CHH and CLP, underscoring the involvement of shared developmental pathways. The high prevalence of FGFR1 variants in patients with CHH and CLP supports its role as a pleiotropic gene. Understanding the overlapping genetic mechanisms may enhance diagnostic precision and inform personalized management strategies for affected individuals.
- 14 January 2026
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (3) , 340-347
Open AccessPleiotropic genes linking congenital hypogonadotropic hypogonadism and cleft lip/palate: evidence from a genomic CHH cohort study
Congenital hypogonadotropic hypogonadism (CHH) is a rare and genetically heterogeneous disorder characterized by absent or incomplete puberty due to impaired gonadotropin-releasing hormone (GnRH) function. A subset of individuals with CHH also present with developmental anomalies, including midline defects such as cleft lip and/or palate (CLP). This study investigates the genetic overlap between CHH and CLP. A total of 336 individuals diagnosed with CHH were clinically assessed for associated phenotypes, including CLP. High-throughput sequencing was performed using a targeted gene panel encompassing known CHH- and CLP-related genes. Variants were analyzed and classified according to the American College of Medical Genetics and Genomics (ACMG) criteria for pathogenicity. CLP was present in 21 patients with CHH (6%). Pathogenic or likely pathogenic variants in genes associated with both CHH and CLP—such as FGFR1 and CHD7 —were identified in eight individuals. Furthermore, 17% of the patients with CHH without CLP harbored deleterious variants in genes implicated in clefting, including DVL3 , PLCB4 , NIPBL , and EDNRA . Evidence of digenic inheritance involving both CHH- and CLP-related genes was observed in multiple cases. FGFR1 variants were the most frequently detected and were commonly associated with anosmia and additional developmental anomalies. These findings highlight a genetic and phenotypic continuum between CHH and CLP, underscoring the involvement of shared developmental pathways. The high prevalence of FGFR1 variants in patients with CHH and CLP supports its role as a pleiotropic gene. Understanding the overlapping genetic mechanisms may enhance diagnostic precision and inform personalized management strategies for affected individuals.
- Open Access
- 4 March 2025
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (2) , fcaf117
Enduring differential patterns of neuronal loss and myelination along 6-month pulsatile gonadotropin-releasing hormone therapy in individuals with Down syndrome
Despite major progress in understanding the impact of the triplicated chromosome 21 on the brain and behaviour in Down syndrome, our knowledge of the underlying neurobiology in humans is still limited. We sought to address some of the pertinent questions about the drivers of brain structure differences and their associations with cognitive function in Down syndrome. To this aim, in a pilot magnetic resonance imaging (MRI) study, we monitored brain anatomy in individuals with Down syndrome receiving pulsatile gonadotropin-releasing hormone (GnRH) therapy over 6 months in comparison with typically developed age- and sex-matched healthy controls. We analysed cross-sectional (Down syndrome/healthy controls n = 11/27; Down syndrome—2 females/9 males, age 26.7 ± 5.0 years old; healthy controls—8 females/19 males, age 24.1 ± 2.5 years old) and longitudinal (Down syndrome/healthy controls n = 8/13; Down syndrome—1 female/7 males, age 26.4 ± 5.3 years old; healthy controls—4 females/9 males, 24.7 ± 2.2 years old) relaxometry and diffusion-weighted MRI data alongside standard cognitive assessment. The statistical tests looked for cross-sectional baseline differences and for differential changes over time between Down syndrome and healthy controls. The post hoc analysis confined to the Down syndrome group, tested for potential time-dependent interactions between individuals’ overall cognitive performance and associated brain anatomy changes. The brain MRI statistical analyses covered both grey and white matter regions across the whole brain allowing for investigation of regional volume, macromolecular/myelin and iron content, additionally to diffusion tensor and neurite orientation and dispersion density characterization across major white matter tracts. The cross-sectional analysis showed reduced frontal, temporal and cerebellar volumes in Down syndrome with only the cerebellar differences remaining significant after adjustment for the presence of microcephaly (Pfamily-wise-corrected < 0.05). The volume reductions were paralleled by decreased cortical and subcortical macromolecular/myelin content confined to the cortical motor system, thalamus and basal ganglia (Pfamily-wise-corrected < 0.05). All major white matter tracts showed a ubiquitous mean diffusivity and intracellular volume fraction reduction contrasted with no differences in magnetization transfer saturation metrics (Pfamily-wise-corrected < 0.05). Compared with healthy controls over the same period, Down syndrome individuals under GnRH therapy showed cognitive improvement (Montreal Cognitive Assessment from 11.4 ± 5.5 to 15.1 ± 5.6; P < 0.01) on the background of stability of the observed differential neuroanatomical patterns. Despite the lack of adequate Down syndrome control group, we interpret the obtained cross-sectional and longitudinal findings in young adults as evidence for predominant neurodevelopmental neuronal loss due to dysfunctional neurogenesis without signs for short-term myelin loss.
- 4 March 2025
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (2) , fcaf117
Open AccessEnduring differential patterns of neuronal loss and myelination along 6-month pulsatile gonadotropin-releasing hormone therapy in individuals with Down syndrome
Despite major progress in understanding the impact of the triplicated chromosome 21 on the brain and behaviour in Down syndrome, our knowledge of the underlying neurobiology in humans is still limited. We sought to address some of the pertinent questions about the drivers of brain structure differences and their associations with cognitive function in Down syndrome. To this aim, in a pilot magnetic resonance imaging (MRI) study, we monitored brain anatomy in individuals with Down syndrome receiving pulsatile gonadotropin-releasing hormone (GnRH) therapy over 6 months in comparison with typically developed age- and sex-matched healthy controls. We analysed cross-sectional (Down syndrome/healthy controls n = 11/27; Down syndrome—2 females/9 males, age 26.7 ± 5.0 years old; healthy controls—8 females/19 males, age 24.1 ± 2.5 years old) and longitudinal (Down syndrome/healthy controls n = 8/13; Down syndrome—1 female/7 males, age 26.4 ± 5.3 years old; healthy controls—4 females/9 males, 24.7 ± 2.2 years old) relaxometry and diffusion-weighted MRI data alongside standard cognitive assessment. The statistical tests looked for cross-sectional baseline differences and for differential changes over time between Down syndrome and healthy controls. The post hoc analysis confined to the Down syndrome group, tested for potential time-dependent interactions between individuals’ overall cognitive performance and associated brain anatomy changes. The brain MRI statistical analyses covered both grey and white matter regions across the whole brain allowing for investigation of regional volume, macromolecular/myelin and iron content, additionally to diffusion tensor and neurite orientation and dispersion density characterization across major white matter tracts. The cross-sectional analysis showed reduced frontal, temporal and cerebellar volumes in Down syndrome with only the cerebellar differences remaining significant after adjustment for the presence of microcephaly (Pfamily-wise-corrected < 0.05). The volume reductions were paralleled by decreased cortical and subcortical macromolecular/myelin content confined to the cortical motor system, thalamus and basal ganglia (Pfamily-wise-corrected < 0.05). All major white matter tracts showed a ubiquitous mean diffusivity and intracellular volume fraction reduction contrasted with no differences in magnetization transfer saturation metrics (Pfamily-wise-corrected < 0.05). Compared with healthy controls over the same period, Down syndrome individuals under GnRH therapy showed cognitive improvement (Montreal Cognitive Assessment from 11.4 ± 5.5 to 15.1 ± 5.6; P < 0.01) on the background of stability of the observed differential neuroanatomical patterns. Despite the lack of adequate Down syndrome control group, we interpret the obtained cross-sectional and longitudinal findings in young adults as evidence for predominant neurodevelopmental neuronal loss due to dysfunctional neurogenesis without signs for short-term myelin loss.
- Open Access
- 8 March 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (5)
Defective jagged-1 signaling affects GnRH development and contributes to congenital hypogonadotropic hypogonadism
In vertebrate species, fertility is controlled by gonadotropin-releasing hormone (GnRH) neurons. GnRH cells arise outside the central nervous system, in the developing olfactory pit, and migrate along olfactory/vomeronasal/terminal nerve axons into the forebrain during embryonic development. Congenital hypogonadotropic hypogonadism (CHH) and Kallmann syndrome are rare genetic disorders characterized by infertility, and they are associated with defects in GnRH neuron migration and/or altered GnRH secretion and signaling. Here, we documented the expression of the jagged-1/Notch signaling pathway in GnRH neurons and along the GnRH neuron migratory route both in zebrafish embryos and in human fetuses. Genetic knockdown of the zebrafish ortholog of JAG1 ( jag1b ) resulted in altered GnRH migration and olfactory axonal projections to the olfactory bulbs. Next-generation sequencing was performed in 467 CHH unrelated probands, leading to the identification of heterozygous rare variants in JAG1 . Functional in vitro validation of JAG1 mutants revealed that 7 out of the 9 studied variants exhibited reduced protein levels and altered subcellular localization. Together our data provide compelling evidence that Jag1/Notch signaling plays a prominent role in the development of GnRH neurons, and we propose that JAG1 insufficiency may contribute to the pathogenesis of CHH in humans.
- 8 March 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (5)
Open AccessDefective jagged-1 signaling affects GnRH development and contributes to congenital hypogonadotropic hypogonadism
In vertebrate species, fertility is controlled by gonadotropin-releasing hormone (GnRH) neurons. GnRH cells arise outside the central nervous system, in the developing olfactory pit, and migrate along olfactory/vomeronasal/terminal nerve axons into the forebrain during embryonic development. Congenital hypogonadotropic hypogonadism (CHH) and Kallmann syndrome are rare genetic disorders characterized by infertility, and they are associated with defects in GnRH neuron migration and/or altered GnRH secretion and signaling. Here, we documented the expression of the jagged-1/Notch signaling pathway in GnRH neurons and along the GnRH neuron migratory route both in zebrafish embryos and in human fetuses. Genetic knockdown of the zebrafish ortholog of JAG1 ( jag1b ) resulted in altered GnRH migration and olfactory axonal projections to the olfactory bulbs. Next-generation sequencing was performed in 467 CHH unrelated probands, leading to the identification of heterozygous rare variants in JAG1 . Functional in vitro validation of JAG1 mutants revealed that 7 out of the 9 studied variants exhibited reduced protein levels and altered subcellular localization. Together our data provide compelling evidence that Jag1/Notch signaling plays a prominent role in the development of GnRH neurons, and we propose that JAG1 insufficiency may contribute to the pathogenesis of CHH in humans.
- Top Cited Papers
- 2 September 2022
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 377 (6610) , 1064-+
GnRH replacement rescues cognition in Down syndrome
At the present time, no viable treatment exists for cognitive and olfactory deficits in Down syndrome (DS). We show in a DS model (Ts65Dn mice) that these progressive nonreproductive neurological symptoms closely parallel a postpubertal decrease in hypothalamic as well as extrahypothalamic expression of a master molecule that controls reproduction—gonadotropin-releasing hormone (GnRH)—and appear related to an imbalance in a microRNA-gene network known to regulate GnRH neuron maturation together with altered hippocampal synaptic transmission. Epigenetic, cellular, chemogenetic, and pharmacological interventions that restore physiological GnRH levels abolish olfactory and cognitive defects in Ts65Dn mice, whereas pulsatile GnRH therapy improves cognition and brain connectivity in adult DS patients. GnRH thus plays a crucial role in olfaction and cognition, and pulsatile GnRH therapy holds promise to improve cognitive deficits in DS.
- 2 September 2022
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 377 (6610) , 1064-+
Top Cited PapersGnRH replacement rescues cognition in Down syndrome
At the present time, no viable treatment exists for cognitive and olfactory deficits in Down syndrome (DS). We show in a DS model (Ts65Dn mice) that these progressive nonreproductive neurological symptoms closely parallel a postpubertal decrease in hypothalamic as well as extrahypothalamic expression of a master molecule that controls reproduction—gonadotropin-releasing hormone (GnRH)—and appear related to an imbalance in a microRNA-gene network known to regulate GnRH neuron maturation together with altered hippocampal synaptic transmission. Epigenetic, cellular, chemogenetic, and pharmacological interventions that restore physiological GnRH levels abolish olfactory and cognitive defects in Ts65Dn mice, whereas pulsatile GnRH therapy improves cognition and brain connectivity in adult DS patients. GnRH thus plays a crucial role in olfaction and cognition, and pulsatile GnRH therapy holds promise to improve cognitive deficits in DS.
- 8 April 2019
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (8) , 1849-1860
Weight loss induced by deep transcranial magnetic stimulation in obesity: A randomized, double‐blind, sham‐controlled study
Aim: To test the hypothesis that deep transcranial magnetic stimulation (dTMS) reduces food craving and causes weight loss via neuromodulation. Materials and methods: This pilot study was designed as a randomized, double‐blind, sham‐controlled study. A total of 33 obese people (nine men, 24 women, mean age 48.1 ± 10.6 years, body mass index [BMI] 36.9 ± 4.7 kg/m 2 ) were randomized and completed the study: 13 participants underwent a 5‐week treatment with high‐frequency (HF) dTMS (18 Hz; HF group), 10 were treated with low‐frequency (LF) dTMS (1 Hz; LF group), and 10 were sham‐treated (sham group). Food craving, and metabolic and neuro‐endocrine variables were evaluated at baseline, after the 5‐week treatment, and at follow‐up visits (1 month, 6 months, 1 year after the end of treatment). Results: The mixed‐model analysis for repeated measures showed a significant interaction of time and groups for body weight ( P = 0.001) and BMI ( P = 0.001), with a significant body weight (−7.83 ± 2.28 kg; P = 0.0009) and BMI (−2.83 ± 0.83, P = 0.0009) decrease in the HF versus the sham group. A decreasing trend in food craving in the HF versus the LF and sham groups ( P = 0.073) was observed. A significant improvement of metabolic and physical activity variables was found ( P < 0.05) in the HF group. Conclusions: We demonstrated the safety and efficacy of dTMS, in addition to physical exercise and a hypocaloric diet, in reducing body weight for up to 1 year in obese people. We hypothesize that a possible mechanism of HF dTMS treatment is modulation of the dopaminergic pathway and stimulation of physical activity.
- 8 April 2019
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (8) , 1849-1860
Weight loss induced by deep transcranial magnetic stimulation in obesity: A randomized, double‐blind, sham‐controlled study
Aim: To test the hypothesis that deep transcranial magnetic stimulation (dTMS) reduces food craving and causes weight loss via neuromodulation. Materials and methods: This pilot study was designed as a randomized, double‐blind, sham‐controlled study. A total of 33 obese people (nine men, 24 women, mean age 48.1 ± 10.6 years, body mass index [BMI] 36.9 ± 4.7 kg/m 2 ) were randomized and completed the study: 13 participants underwent a 5‐week treatment with high‐frequency (HF) dTMS (18 Hz; HF group), 10 were treated with low‐frequency (LF) dTMS (1 Hz; LF group), and 10 were sham‐treated (sham group). Food craving, and metabolic and neuro‐endocrine variables were evaluated at baseline, after the 5‐week treatment, and at follow‐up visits (1 month, 6 months, 1 year after the end of treatment). Results: The mixed‐model analysis for repeated measures showed a significant interaction of time and groups for body weight ( P = 0.001) and BMI ( P = 0.001), with a significant body weight (−7.83 ± 2.28 kg; P = 0.0009) and BMI (−2.83 ± 0.83, P = 0.0009) decrease in the HF versus the sham group. A decreasing trend in food craving in the HF versus the LF and sham groups ( P = 0.073) was observed. A significant improvement of metabolic and physical activity variables was found ( P < 0.05) in the HF group. Conclusions: We demonstrated the safety and efficacy of dTMS, in addition to physical exercise and a hypocaloric diet, in reducing body weight for up to 1 year in obese people. We hypothesize that a possible mechanism of HF dTMS treatment is modulation of the dopaminergic pathway and stimulation of physical activity.
- 8 November 2018
- Published by Springer Nature in Endocrine
- Vol. 64 (1) , 67-74
High frequency deep transcranial magnetic stimulation acutely increases β-endorphins in obese humans
Purpose In obesity, metabolic and voluntary factors regulate appetite, and a dysregulation of the reward pathway was demonstrated in all addiction disorders. Deep transcranial magnetic stimulation (dTMS) is already used to modulate cerebral dopamine activation in neuro-psychiatric diseases. We presently assess the acute effect of high frequency (HF) and low frequency (LF) dTMS on the modulation of the main neuropeptides and neurotransmitters involved in the reward pathway in obese subjects. Methods This study was designed as a double-blind, sham-controlled, randomized clinical trial. Thirty-three obese patients (9 males, 24 females, age 48.1 ± 10.6, BMI 36.4 ± 4.7) were enrolled in the study. All patients were studied during a single dTMS session and blood aliquots were drawn before and after a single dTMS session. Metabolic and neuro-endocrine parameters were evaluated before and after: (1) 18 Hz dTMS (HF, 13 patients); (2) 1 Hz dTMS (LF, 10 patients); (3) Sham treatment (Sham, 10 patients). Results No statistically significant variations in metabolic parameters, systolic and diastolic blood pressure, and heart rate were shown acutely. HF showed a significant increase of β-endorphin compared to other groups (p = 0.048); a significant increase of ghrelin in LF (p = 0.041) was also demonstrated. Conclusions A single session of HF dTMS treatment determines in obese subjects an acute increase of β-endorphin level, indicating an activation of the reward pathway. The present findings constitute proof of principle for a potential application of this methodology in obesity treatment.
- 8 November 2018
- Published by Springer Nature in Endocrine
- Vol. 64 (1) , 67-74
High frequency deep transcranial magnetic stimulation acutely increases β-endorphins in obese humans
Purpose In obesity, metabolic and voluntary factors regulate appetite, and a dysregulation of the reward pathway was demonstrated in all addiction disorders. Deep transcranial magnetic stimulation (dTMS) is already used to modulate cerebral dopamine activation in neuro-psychiatric diseases. We presently assess the acute effect of high frequency (HF) and low frequency (LF) dTMS on the modulation of the main neuropeptides and neurotransmitters involved in the reward pathway in obese subjects. Methods This study was designed as a double-blind, sham-controlled, randomized clinical trial. Thirty-three obese patients (9 males, 24 females, age 48.1 ± 10.6, BMI 36.4 ± 4.7) were enrolled in the study. All patients were studied during a single dTMS session and blood aliquots were drawn before and after a single dTMS session. Metabolic and neuro-endocrine parameters were evaluated before and after: (1) 18 Hz dTMS (HF, 13 patients); (2) 1 Hz dTMS (LF, 10 patients); (3) Sham treatment (Sham, 10 patients). Results No statistically significant variations in metabolic parameters, systolic and diastolic blood pressure, and heart rate were shown acutely. HF showed a significant increase of β-endorphin compared to other groups (p = 0.048); a significant increase of ghrelin in LF (p = 0.041) was also demonstrated. Conclusions A single session of HF dTMS treatment determines in obese subjects an acute increase of β-endorphin level, indicating an activation of the reward pathway. The present findings constitute proof of principle for a potential application of this methodology in obesity treatment.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Deep transcranial magnetic stimulation acutely modulates neuro-endocrine pathways underlying obesity
Deep Transcranical Magnetic Stimulation (dTMS) is a non-invasive modulation technique of cortical excitability that has shown to affect the mesolimbic and mesostriatal dopaminergic pathways. Consistent with these assets, dTMS is widely used as a therapeutic tool in neuro-psychiatric disorders associated with abnormal cortical excitability and dopaminergic activity, as addiction. Hence, considering the dysfuncional role of PFC and dopaminergic reward system in controlling appetite, dTMS was suggested to be affective in reducing food craving and in controlling body weight in obese subjects. However, the underlying physiological mechanisms of the dTMS effects are not fully know. Aim of this study was to investigate the effects of a single dTMS session on neuro-endocrine pathways in obesity. Fourty obese patients (11 M, 29 M; age: 48.0±1.6; BMI: 36.3±0.7) were assigned to receive one session of high frequency (18 Hz, HF), low frequency (1 Hz, LF) or Sham stimulation via an H-coil dTMS. H-coil was targeted to stimulate Prefrontal Cortex and Insula, bilaterally. Metabolic and neuro-endocrine parameters were evaluated before and after a single dTMS session. Following the 18 Hz dTMS session, a significant increase of norepinephrine was found (5.6±0.9 vs 6.5±1.2 ng/ml, +18.0±6.8%, P=0.01; P=0.05 vs LF); a rise in β-endorphins levels was also shown (0.338±0.049 vs 0.372±0.048 ng/ml, +13.9±4.6%, P=0.017; P=0.010 vs Sham; P=0.011 vs LF). In the same group, glucose levels significantly increased (90.2±4.1 vs 96.2±4.2 mg/dl, +7.0±1.8%, P=0.002), whilst leptin levels significantly decreased (66.9±10.5 vs 56.3±9.0 ng/ml, −16.3±3.0%, P=0.002). Furthermore, pituitary hormones significantly decreased after a single 18 Hz dTMS session, specifically TSH (2.71±0.25 vs 2.09±0.18 μU/ml, −20.7±4.7%, P=0.001) and prolactin (17.1±1.3 vs 10.6±0.8 ng/ml, −34.7±4.7%, PP=0.015). These results suggest that dTMS can acutely affect orexygenic pathways and metabolic parameters mainly via modulation of the sympathetic activity and hypothalamic-pituitary-adrenal axis. The increase of β-endorphins could suggest a potential role of HF dTMS in inducing the dopaminergic system activation and therefore, in modulating the food reward system. Together these findings support the role of dTMS as a novel promising treatment for obesity.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Deep transcranial magnetic stimulation acutely modulates neuro-endocrine pathways underlying obesity
Deep Transcranical Magnetic Stimulation (dTMS) is a non-invasive modulation technique of cortical excitability that has shown to affect the mesolimbic and mesostriatal dopaminergic pathways. Consistent with these assets, dTMS is widely used as a therapeutic tool in neuro-psychiatric disorders associated with abnormal cortical excitability and dopaminergic activity, as addiction. Hence, considering the dysfuncional role of PFC and dopaminergic reward system in controlling appetite, dTMS was suggested to be affective in reducing food craving and in controlling body weight in obese subjects. However, the underlying physiological mechanisms of the dTMS effects are not fully know. Aim of this study was to investigate the effects of a single dTMS session on neuro-endocrine pathways in obesity. Fourty obese patients (11 M, 29 M; age: 48.0±1.6; BMI: 36.3±0.7) were assigned to receive one session of high frequency (18 Hz, HF), low frequency (1 Hz, LF) or Sham stimulation via an H-coil dTMS. H-coil was targeted to stimulate Prefrontal Cortex and Insula, bilaterally. Metabolic and neuro-endocrine parameters were evaluated before and after a single dTMS session. Following the 18 Hz dTMS session, a significant increase of norepinephrine was found (5.6±0.9 vs 6.5±1.2 ng/ml, +18.0±6.8%, P=0.01; P=0.05 vs LF); a rise in β-endorphins levels was also shown (0.338±0.049 vs 0.372±0.048 ng/ml, +13.9±4.6%, P=0.017; P=0.010 vs Sham; P=0.011 vs LF). In the same group, glucose levels significantly increased (90.2±4.1 vs 96.2±4.2 mg/dl, +7.0±1.8%, P=0.002), whilst leptin levels significantly decreased (66.9±10.5 vs 56.3±9.0 ng/ml, −16.3±3.0%, P=0.002). Furthermore, pituitary hormones significantly decreased after a single 18 Hz dTMS session, specifically TSH (2.71±0.25 vs 2.09±0.18 μU/ml, −20.7±4.7%, P=0.001) and prolactin (17.1±1.3 vs 10.6±0.8 ng/ml, −34.7±4.7%, PP=0.015). These results suggest that dTMS can acutely affect orexygenic pathways and metabolic parameters mainly via modulation of the sympathetic activity and hypothalamic-pituitary-adrenal axis. The increase of β-endorphins could suggest a potential role of HF dTMS in inducing the dopaminergic system activation and therefore, in modulating the food reward system. Together these findings support the role of dTMS as a novel promising treatment for obesity.
- 9 July 2017
- Published by Taylor & Francis in International Journal of Food Sciences and Nutrition
- Vol. 69 (2) , 223-234
Effects of hazelnuts and cocoa on vascular reactivity in healthy subjects: a randomised study
- 9 July 2017
- Published by Taylor & Francis in International Journal of Food Sciences and Nutrition
- Vol. 69 (2) , 223-234
Effects of hazelnuts and cocoa on vascular reactivity in healthy subjects: a randomised study
- Open Access
- 19 June 2017
- Published by Wiley in Journal of Diabetes Research
- Vol. 2017, 1-10
Effect of Sugar versus Mixed Breakfast on Metabolic and Neurofunctional Responses in Healthy Individuals
We investigated the effects of glucose and diverse breakfasts on glucose increment and ghrelin suppression and cognitive processing of sensory information assessed by frontal P300 evoked potentials. In a randomized crossover design, 12 healthy individuals (6M/6F; BMI 22.2 ± 0.4 kg/m2; 27 ± 1.3 years, mean ± SEM) underwent 50 g OGTT (A) and 3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream) to assess plasma glucose-, insulin-, and ghrelin excursions. An electroencephalography was performed before and 100 min after consumption of each load to measure the latency of frontal P300 evoked potentials as index of cognitive performance. Breakfasts B1 and B2 exhibited significantly lower glycemic and insulinemic responses as compared to A. Breakfast B3 exhibited significantly lower glycemic, but not insulinemic response, as compared to A. Final plasma ghrelin inhibition was more pronounced, albeit not significantly, in all breakfasts with respect to A. P300 latency tended to decrease following each of the three breakfasts, but B3 was the only breakfast capable to elicit a statistically significant reduction in P300 latency with respect to A (), suggesting ameliorated cognitive performance. Such amelioration was correlated with the 2-hour final inhibition of plasma ghrelin concentration (,).- 19 June 2017
- Published by Wiley in Journal of Diabetes Research
- Vol. 2017, 1-10
Open AccessEffect of Sugar versus Mixed Breakfast on Metabolic and Neurofunctional Responses in Healthy Individuals
We investigated the effects of glucose and diverse breakfasts on glucose increment and ghrelin suppression and cognitive processing of sensory information assessed by frontal P300 evoked potentials. In a randomized crossover design, 12 healthy individuals (6M/6F; BMI 22.2 ± 0.4 kg/m2; 27 ± 1.3 years, mean ± SEM) underwent 50 g OGTT (A) and 3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream) to assess plasma glucose-, insulin-, and ghrelin excursions. An electroencephalography was performed before and 100 min after consumption of each load to measure the latency of frontal P300 evoked potentials as index of cognitive performance. Breakfasts B1 and B2 exhibited significantly lower glycemic and insulinemic responses as compared to A. Breakfast B3 exhibited significantly lower glycemic, but not insulinemic response, as compared to A. Final plasma ghrelin inhibition was more pronounced, albeit not significantly, in all breakfasts with respect to A. P300 latency tended to decrease following each of the three breakfasts, but B3 was the only breakfast capable to elicit a statistically significant reduction in P300 latency with respect to A (), suggesting ameliorated cognitive performance. Such amelioration was correlated with the 2-hour final inhibition of plasma ghrelin concentration (,). - Open Access
- 1 January 2017
- Published by SAGE Publications in Cell Transplantation
- Vol. 26 (1) , 23-32
Active Subjects with Autoimmune Type 1 Diabetes have Better Metabolic Profiles than Sedentary Controls
Previous studies in humans with type 1 diabetes mellitus (T1D) and in nonobese diabetic mice have investigated the beneficial immunomodulatory potential of aerobic physical activity. Performing high volume of aerobic exercise may favorably regulate autoimmunity in diabetes. We tested whether increased physical activity is a self-sufficient positive factor in T1D subjects. During a 3-month observational period, active (six males; 40.5 ± 6.1 years; BMI: 24.5 ± 2.1) and sedentary (four males, three females; 35.9 ± 8.9 years; BMI: 25.7 ± 3.8) T1D individuals on insulin pump therapy were studied for metabolic, inflammatory, and autoimmune parameters. At baseline and at the end of a 3-month period, glycosylated hemoglobin (HbA1c), autoantibodies (anti-GAD, anti-ZnT8, anti-IA2, and ICA) and proinflammatory cytokines (IL-6 and TNF-α) were evaluated. During the third month of the period, physically active T1D patients showed a significant reduction in the average glucose levels (-9%, p = 0.025, by CGM) compared to the first month values, and even their hyperglycemic episodes (>180 mg/dl) diminished significantly (-24.2%, p = 0.032 vs. first month). Moreover, active T1D subjects exhibited an improved body composition with respect to sedentary controls. No significant changes were detected as to the autoimmune and inflammatory profiles. This study confirms the beneficial role of physical exercise associated with insulin pump therapy in order to improve metabolic control in individuals with T1D. These preliminary positive observations need to be challenged in a prolonged interventional follow-up.
- 1 January 2017
- Published by SAGE Publications in Cell Transplantation
- Vol. 26 (1) , 23-32
Open AccessActive Subjects with Autoimmune Type 1 Diabetes have Better Metabolic Profiles than Sedentary Controls
Previous studies in humans with type 1 diabetes mellitus (T1D) and in nonobese diabetic mice have investigated the beneficial immunomodulatory potential of aerobic physical activity. Performing high volume of aerobic exercise may favorably regulate autoimmunity in diabetes. We tested whether increased physical activity is a self-sufficient positive factor in T1D subjects. During a 3-month observational period, active (six males; 40.5 ± 6.1 years; BMI: 24.5 ± 2.1) and sedentary (four males, three females; 35.9 ± 8.9 years; BMI: 25.7 ± 3.8) T1D individuals on insulin pump therapy were studied for metabolic, inflammatory, and autoimmune parameters. At baseline and at the end of a 3-month period, glycosylated hemoglobin (HbA1c), autoantibodies (anti-GAD, anti-ZnT8, anti-IA2, and ICA) and proinflammatory cytokines (IL-6 and TNF-α) were evaluated. During the third month of the period, physically active T1D patients showed a significant reduction in the average glucose levels (-9%, p = 0.025, by CGM) compared to the first month values, and even their hyperglycemic episodes (>180 mg/dl) diminished significantly (-24.2%, p = 0.032 vs. first month). Moreover, active T1D subjects exhibited an improved body composition with respect to sedentary controls. No significant changes were detected as to the autoimmune and inflammatory profiles. This study confirms the beneficial role of physical exercise associated with insulin pump therapy in order to improve metabolic control in individuals with T1D. These preliminary positive observations need to be challenged in a prolonged interventional follow-up.